\n| \n \n\u00a0<\/p>\n<\/td>\n | \n First Quarter<\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n \n$ in millions<\/p>\n<\/td>\n | \n 2023<\/b><\/p>\n<\/td>\n | | \n\n 2022<\/b><\/p>\n<\/td>\n | | \n\n Change<\/b><\/p>\n<\/td>\n | | \n\n Change Ex-
\n
Exchange<\/b><\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nTotal Sales<\/p>\n<\/td>\n | \n \n$14,487<\/p>\n<\/td>\n | | \n\n \n$15,901<\/p>\n<\/td>\n | | \n\n \n-9%<\/p>\n<\/td>\n | | \n\n \n-5%<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nPharmaceutical<\/p>\n<\/td>\n | \n \n12,721<\/p>\n<\/td>\n | | \n\n \n14,107<\/p>\n<\/td>\n | | \n\n \n-10%<\/p>\n<\/td>\n | | \n\n \n-6%<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nKEYTRUDA<\/p>\n<\/td>\n | \n \n5,795<\/p>\n<\/td>\n | | \n\n \n4,809<\/p>\n<\/td>\n | | \n\n \n20%<\/p>\n<\/td>\n | | \n\n \n24%<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nGARDASIL \/ GARDASIL 9<\/p>\n<\/td>\n | \n \n1,972<\/p>\n<\/td>\n | | \n\n \n1,460<\/p>\n<\/td>\n | | \n\n \n35%<\/p>\n<\/td>\n | | \n\n \n43%<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nJANUVIA \/ JANUMET<\/p>\n<\/td>\n | \n \n880<\/p>\n<\/td>\n | | \n\n \n1,233<\/p>\n<\/td>\n | | \n\n \n-29%<\/p>\n<\/td>\n | | \n\n \n-25%<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nPROQUAD, M-M-R II and VARIVAX<\/p>\n<\/td>\n | \n \n528<\/p>\n<\/td>\n | | \n\n \n470<\/p>\n<\/td>\n | | \n\n \n12%<\/p>\n<\/td>\n | | \n\n \n14%<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nBRIDION<\/p>\n<\/td>\n | \n \n487<\/p>\n<\/td>\n | | \n\n \n395<\/p>\n<\/td>\n | | \n\n \n23%<\/p>\n<\/td>\n | | \n\n \n27%<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nLAGEVRIO<\/p>\n<\/td>\n | \n \n392<\/p>\n<\/td>\n | | \n\n \n3,247<\/p>\n<\/td>\n | | \n\n \n-88%<\/p>\n<\/td>\n | | \n\n \n-87%<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nROTATEQ<\/p>\n<\/td>\n | \n \n297<\/p>\n<\/td>\n | | \n\n \n216<\/p>\n<\/td>\n | | \n\n \n38%<\/p>\n<\/td>\n | | \n\n \n42%<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nLynparza*<\/p>\n<\/td>\n | \n \n275<\/p>\n<\/td>\n | | \n\n \n266<\/p>\n<\/td>\n | | \n\n \n3%<\/p>\n<\/td>\n | | \n\n \n8%<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nLenvima*<\/p>\n<\/td>\n | \n \n232<\/p>\n<\/td>\n | | \n\n \n227<\/p>\n<\/td>\n | | \n\n \n2%<\/p>\n<\/td>\n | | \n\n \n5%<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nSIMPONI<\/p>\n<\/td>\n | \n \n180<\/p>\n<\/td>\n | | \n\n \n186<\/p>\n<\/td>\n | | \n\n \n-3%<\/p>\n<\/td>\n | | \n\n \n2%<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nAnimal Health<\/p>\n<\/td>\n | \n \n1,491<\/p>\n<\/td>\n | | \n\n \n1,482<\/p>\n<\/td>\n | | \n\n \n1%<\/p>\n<\/td>\n | | \n\n \n5%<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nLivestock<\/p>\n<\/td>\n | \n \n849<\/p>\n<\/td>\n | | \n\n \n832<\/p>\n<\/td>\n | | \n\n \n2%<\/p>\n<\/td>\n | | \n\n \n8%<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nCompanion Animals<\/p>\n<\/td>\n | \n \n642<\/p>\n<\/td>\n | | \n\n \n650<\/p>\n<\/td>\n | | \n\n \n-1%<\/p>\n<\/td>\n | | \n\n \n2%<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nOther Revenues**<\/p>\n<\/td>\n | \n \n275<\/p>\n<\/td>\n | | \n\n \n312<\/p>\n<\/td>\n | | \n\n \n-12%<\/p>\n<\/td>\n | | \n\n \n-22%<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \n*Alliance revenue for this product represents Merck\u2019s share of profits, which are product sales net of cost of sales and commercialization costs.<\/p>\n<\/td>\n<\/tr>\n | \n| \n \n**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n Pharmaceutical Revenue<\/span><\/b><\/p>\n\nFirst-quarter Pharmaceutical sales declined 10% to $12.7 billion, primarily due to lower sales in virology, largely attributable to LAGEVRIO, and diabetes, partially offset by growth in oncology, vaccines and hospital acute care. Excluding LAGEVRIO, Pharmaceutical sales grew 14%, and excluding LAGEVRIO and the unfavorable impact of foreign exchange, Pharmaceutical sales grew 18%.<\/p>\n \nThe decline in virology was primarily due to lower sales of LAGEVRIO, which decreased 88% to $392 million, largely attributable to sales in the U.S. and U.K. markets in the first quarter of 2022 that did not recur in the first quarter of 2023. The LAGEVRIO sales decline was also attributable to lower sales in Japan and Australia.<\/p>\n \nThe sales decline within diabetes primarily reflects lower combined sales of JANUVIA (sitagliptin) and JANUMET (sitagliptin and metformin HCI), which declined 29% to $880 million, primarily due to generic competition in several international markets, particularly in Europe, and lower demand and pricing in the U.S.<\/p>\n \nGrowth in oncology was largely driven by higher sales of KEYTRUDA, which rose 20% to $5.8 billion in the quarter. Global sales growth of KEYTRUDA reflects continued strong momentum from metastatic indications, including certain types of NSCLC, renal cell carcinoma, head and neck squamous cell carcinoma, triple-negative breast cancer (TNBC) and microsatellite instability-high (MSI-H) cancers, and increased uptake across recent earlier-stage launches, including certain types of neoadjuvant\/adjuvant TNBC in the U.S.<\/p>\n \nGrowth in vaccines reflects higher combined sales of GARDASIL (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), which grew 35% to $2.0 billion, reflecting strong demand outside of the U.S., particularly in China, which also benefited from the timing of shipments and increased supply. Growth in vaccines also reflects higher sales of VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine), which increased to $106 million, primarily due to continued uptake in the pediatric indication following launch in the U.S. In addition, vaccines sales performance reflects higher sales of ROTATEQ (Rotavirus Vaccine, Live Oral, Pentavalent), which grew 38% to $297 million, primarily due to inventory stocking in China. Growth in vaccines was partially offset by lower sales of PNEUMOVAX 23 (pneumococcal vaccine polyvalent), which declined 44% to $96 million, primarily reflecting lower U.S. demand as the market continues to shift toward newer adult pneumococcal conjugate vaccines.<\/p>\n \nGrowth in hospital acute care reflects higher sales of BRIDION (sugammadex) injection 100 mg\/ML, which grew 23% to $487 million, primarily due to increased demand, particularly in the U.S., reflecting an increase in its share among neuromuscular blockade reversal agents.<\/p>\n Animal Health Revenue<\/span><\/b><\/p>\n\nAnimal Health sales totaled $1.5 billion for the first quarter of 2023, a 1% increase compared with the first quarter of 2022. Excluding the impact of foreign exchange, Animal Health sales increased 5%. Growth in livestock products reflects strong demand notably in the ruminant and poultry product portfolio, which includes technology solution products, as well as higher pricing. Excluding the unfavorable impact of foreign exchange, growth in companion animal products reflects the impact of higher pricing. The BRAVECTO (fluralaner) parasiticide line of products had sales of $314 million in the quarter.<\/p>\n First-Quarter Expense, EPS and Related Information<\/span><\/b><\/p>\n\nThe tables below present selected expense information.<\/p>\n \n\n| \n \n$ in millions<\/p>\n<\/td>\n | \n GAAP<\/b><\/p>\n<\/td>\n | | \n | \n\n Acquisition- and Divestiture-Related Costs<\/b>4<\/sup><\/p>\n<\/td>\n | \n | \n\n Restructuring Costs<\/b><\/p>\n<\/td>\n | | \n | \n\n (Income) Loss From Investments in Equity Securities<\/b><\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n \n\u00a0<\/p>\n Certain Other Items<\/b><\/p>\n<\/td>\n | | \n\n Non-GAAP<\/b>2<\/sup><\/p>\n<\/td>\n | <\/tr>\n\n| \n First Quarter 2023<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n | \n\n \n\u00a0<\/p>\n<\/td>\n | | \n | \n\n \n\u00a0<\/p>\n<\/td>\n | | \n | \n\n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nCost of sales<\/p>\n<\/td>\n | \n \n$3,926<\/p>\n<\/td>\n | | \n | \n\n \n$545<\/p>\n<\/td>\n | | \n | \n\n \n$29<\/p>\n<\/td>\n | | \n | \n\n \n$-<\/p>\n<\/td>\n | | \n\n \n$-<\/p>\n<\/td>\n | | \n\n \n$3,352<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nSelling, general and administrative<\/p>\n<\/td>\n | \n \n2,479<\/p>\n<\/td>\n | | \n | \n\n \n20<\/p>\n<\/td>\n | | \n | \n\n \n1<\/p>\n<\/td>\n | | \n | \n\n \n–<\/p>\n<\/td>\n | | \n\n \n–<\/p>\n<\/td>\n | | \n\n \n2,458<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nResearch and development<\/p>\n<\/td>\n | \n \n4,276<\/p>\n<\/td>\n | | \n | \n\n \n10<\/p>\n<\/td>\n | | \n | \n\n \n–<\/p>\n<\/td>\n | | \n | \n\n \n–<\/p>\n<\/td>\n | | \n\n \n–<\/p>\n<\/td>\n | | \n\n \n4,266<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nRestructuring costs<\/p>\n<\/td>\n | \n \n67<\/p>\n<\/td>\n | | \n | \n\n \n–<\/p>\n<\/td>\n | | \n | \n\n \n67<\/p>\n<\/td>\n | | \n | \n\n \n–<\/p>\n<\/td>\n | | \n\n \n–<\/p>\n<\/td>\n | | \n\n \n–<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nOther (income) expense, net<\/p>\n<\/td>\n | \n \n89<\/p>\n<\/td>\n | | \n | \n\n \n15<\/p>\n<\/td>\n | | \n | \n\n \n–<\/p>\n<\/td>\n | | \n | \n\n \n(429)<\/p>\n<\/td>\n | | \n\n \n573<\/p>\n<\/td>\n | | \n\n \n(70)<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n | \n\n \n\u00a0<\/p>\n<\/td>\n | | \n | \n\n \n\u00a0<\/p>\n<\/td>\n | | \n | \n\n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | | <\/tr>\n \n| \n First Quarter 2022<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n | \n\n \n\u00a0<\/p>\n<\/td>\n | | \n | \n\n \n\u00a0<\/p>\n<\/td>\n | | \n | \n\n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nCost of sales<\/p>\n<\/td>\n | \n \n$5,380<\/p>\n<\/td>\n | | \n | \n\n \n$680<\/p>\n<\/td>\n | | \n | \n\n \n$46<\/p>\n<\/td>\n | | \n | \n\n \n$-<\/p>\n<\/td>\n | | \n\n \n$-<\/p>\n<\/td>\n | | \n\n \n$4,654<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nSelling, general and administrative<\/p>\n<\/td>\n | \n \n2,323<\/p>\n<\/td>\n | | \n | \n\n \n50<\/p>\n<\/td>\n | | \n | \n\n \n21<\/p>\n<\/td>\n | | \n | \n\n \n–<\/p>\n<\/td>\n | | \n\n \n–<\/p>\n<\/td>\n | | \n\n \n2,252<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nResearch and development<\/p>\n<\/td>\n | \n \n2,576<\/p>\n<\/td>\n | | \n | \n\n \n22<\/p>\n<\/td>\n | | \n | \n\n \n7<\/p>\n<\/td>\n | | \n | \n\n \n–<\/p>\n<\/td>\n | | \n\n \n–<\/p>\n<\/td>\n | | \n\n \n2,547<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nRestructuring costs<\/p>\n<\/td>\n | \n \n53<\/p>\n<\/td>\n | | \n | \n\n \n–<\/p>\n<\/td>\n | | \n | \n\n \n53<\/p>\n<\/td>\n | | \n | \n\n \n–<\/p>\n<\/td>\n | | \n\n \n–<\/p>\n<\/td>\n | | \n\n \n–<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nOther (income) expense, net<\/p>\n<\/td>\n | \n \n708<\/p>\n<\/td>\n | | \n | \n\n \n(115)<\/p>\n<\/td>\n | | \n | \n\n \n–<\/p>\n<\/td>\n | | \n | \n\n \n684<\/p>\n<\/td>\n | | \n\n \n–<\/p>\n<\/td>\n | | \n\n \n139<\/p>\n<\/td>\n | | <\/tr>\n<\/table>\nGAAP Expense, EPS and Related Information<\/span><\/b><\/p>\n\nGross margin was 72.9% for the first quarter of 2023 compared with 66.2% for the first quarter of 2022. The increase primarily reflects lower LAGEVRIO sales, which have a low gross margin, as well as the favorable impacts of product mix and lower amortization of intangible assets.<\/p>\n \nSelling, general and administrative (SG&A) expenses were $2.5 billion in the first quarter of 2023, an increase of 7% compared with the first quarter of 2022. The increase primarily reflects higher administrative costs and higher promotional spending, partially offset by the favorable impact of foreign exchange.<\/p>\n \nR&D expenses were $4.3 billion in the first quarter of 2023, an increase of 66% compared with the first quarter of 2022. The increase was primarily driven by a $1.2 billion charge for the acquisition of Imago and a $175 million charge related to a collaboration and licensing agreement with Kelun-Biotech. In addition, the increase was driven by higher compensation and benefit costs, reflecting in part increased headcount to support expanded clinical development activity, higher investments in discovery research and early drug development, and higher clinical development spending.<\/p>\n \nOther (income) expense, net, was $89 million of expense in the first quarter of 2023 compared with $708 million of expense in the first quarter of 2022. The change is primarily due to net gains from investments in equity securities in the first quarter of 2023 compared with net losses from investments in equity securities in the first quarter of 2022, as well as higher interest income in the first quarter of 2023. The favorability was partially offset by a $573 million charge in the first quarter of 2023 related to settlements with certain plaintiffs in the Zetia antitrust litigation.<\/p>\n \nThe effective tax rate of 22.6% for the first quarter of 2023 reflects the unfavorable discrete impact of a charge for the acquisition of Imago for which no tax benefit was recognized, as well as the unfavorable effects of higher foreign taxes, the R&D capitalization provision of the Tax Cuts and Jobs Act of 2017, and net unrealized gains from investments in equity securities, which were taxed at the U.S. tax rate.<\/p>\n \nGAAP EPS was $1.11 for the first quarter of 2023 compared with $1.70 for the first quarter of 2022.<\/p>\n Non-GAAP Expense, EPS and Related Information<\/span><\/b><\/p>\n\nNon-GAAP gross margin was 76.9% for the first quarter of 2023 compared with 70.7% for the first quarter of 2022. The increase primarily reflects lower LAGEVRIO sales, which have a low gross margin, as well as the favorable impact of product mix.<\/p>\n \nNon-GAAP SG&A expenses were $2.5 billion in the first quarter of 2023, an increase of 9% compared with the first quarter of 2022. The increase primarily reflects higher administrative costs and higher promotional spending, partially offset by the favorable impact of foreign exchange.<\/p>\n \nNon-GAAP R&D expenses were $4.3 billion in the first quarter of 2023, an increase of 67% compared with the first quarter of 2022. The increase was primarily driven by a $1.2 billion charge for the acquisition of Imago and a $175 million charge related to a collaboration and licensing agreement with Kelun-Biotech. In addition, the increase was driven by higher compensation and benefit costs, reflecting in part increased headcount to support expanded clinical development activity, higher investments in discovery research and early drug development, and higher clinical development spending.<\/p>\n \nNon-GAAP other (income) expense, net, was $70 million of income in the first quarter of 2023 compared with $139 million of expense in the first quarter of 2022, primarily reflecting higher interest income in the first quarter of 2023.<\/p>\n \nThe non-GAAP effective tax rate of 20.4% for the first quarter of 2023 reflects the unfavorable discrete impact of a charge for the acquisition of Imago for which no tax benefit was recognized, as well as the unfavorable effects of higher foreign taxes and the R&D capitalization provision of the Tax Cuts and Jobs Act of 2017.<\/p>\n \nNon-GAAP EPS was $1.40 for the first quarter of 2023 compared with $2.14 for the first quarter of 2022.<\/p>\n \nA reconciliation of GAAP to non-GAAP net income and EPS is provided in the table that follows.<\/p>\n \n\n | \n\n First Quarter<\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n \n$ in millions, except EPS amounts<\/p>\n<\/td>\n | \n 2023<\/b><\/p>\n<\/td>\n | | \n\n 2022<\/b><\/p>\n<\/td>\n | | <\/tr>\n \n| \n EPS<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nGAAP EPS<\/p>\n<\/td>\n | \n \n$1.11<\/p>\n<\/td>\n | | \n\n \n$1.70<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nDifference<\/p>\n<\/td>\n | \n \n0.29<\/p>\n<\/td>\n | | \n\n \n0.44<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nNon-GAAP EPS that excludes items listed below2<\/sup><\/p>\n<\/td>\n| \n \n$1.40<\/p>\n<\/td>\n | | \n\n \n$2.14<\/p>\n<\/td>\n | | <\/tr>\n\n| \n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | | <\/tr>\n \n| \n Net Income<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nGAAP net income1<\/sup><\/p>\n<\/td>\n| \n \n$2,821<\/p>\n<\/td>\n | | \n\n \n$4,310<\/p>\n<\/td>\n | | <\/tr>\n\n| \n \nDifference<\/p>\n<\/td>\n | \n \n743<\/p>\n<\/td>\n | | \n\n \n1,119<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nNon-GAAP net income that excludes items listed below1,2<\/sup><\/p>\n<\/td>\n| \n \n$3,564<\/p>\n<\/td>\n | | \n\n \n$5,429<\/p>\n<\/td>\n | | <\/tr>\n\n| \n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | | <\/tr>\n \n| \n Decrease (Increase) in Net Income Due to Excluded Items:<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nAcquisition- and divestiture-related costs4<\/sup><\/p>\n<\/td>\n| \n \n$590<\/p>\n<\/td>\n | | \n\n \n$637<\/p>\n<\/td>\n | | <\/tr>\n\n| \n \nRestructuring costs<\/p>\n<\/td>\n | \n \n97<\/p>\n<\/td>\n | | \n\n \n127<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \n(Income) loss from investments in equity securities<\/p>\n<\/td>\n | \n \n(429)<\/p>\n<\/td>\n | | \n\n \n684<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nCharge for Zetia antitrust litigation settlements<\/p>\n<\/td>\n | \n \n573<\/p>\n<\/td>\n | | \n\n \n–<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nNet decrease (increase) in income before taxes<\/p>\n<\/td>\n | \n \n831<\/p>\n<\/td>\n | | \n\n \n1,448<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nEstimated income tax (benefit) expense<\/p>\n<\/td>\n | \n \n(88)<\/p>\n<\/td>\n | | \n\n \n(329)<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nDecrease (increase) in net income<\/p>\n<\/td>\n | \n \n$743<\/p>\n<\/td>\n | | \n\n \n$1,119<\/p>\n<\/td>\n | | <\/tr>\n<\/table>\nFinancial Outlook<\/span><\/b><\/p>\n\nThe following table summarizes the company\u2019s full-year 2023 financial outlook.<\/p>\n \n\n | \n\n GAAP<\/b><\/p>\n<\/td>\n | | \n\n Non-GAAP<\/b>2<\/sup><\/p>\n<\/td>\n | <\/tr>\n\n| \n \nSales*<\/p>\n<\/td>\n | \n \n$57.7 to $58.9 billion<\/p>\n<\/td>\n | | \n\n \n$57.7 to $58.9 billion<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nGross margin<\/p>\n<\/td>\n | \n \nApproximately 73%<\/p>\n<\/td>\n | | \n\n \nApproximately 77%<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nOperating expenses**<\/p>\n<\/td>\n | \n \n$23.5 to $24.3 billion<\/p>\n<\/td>\n | | \n\n \n$23.3 to $24.1 billion<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nEffective tax rate<\/p>\n<\/td>\n | \n \n17% to 18%<\/p>\n<\/td>\n | | \n\n \n17% to 18%<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nEPS***<\/p>\n<\/td>\n | \n \n$5.85 to $5.97<\/p>\n<\/td>\n | | \n\n \n$6.88 to $7.00<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \n*Includes approximately $1.0 billion of LAGEVRIO sales. The company does not have any non-GAAP adjustments to sales.<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \n**Includes an aggregate $1.4 billion of R&D expenses related to the Imago acquisition and upfront payment for the license and collaboration agreement with Kelun-Biotech. Outlook does not assume the proposed acquisition of Prometheus or any additional significant potential business development transactions.<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \n***Includes $0.52 of charges related to the Imago acquisition and upfront payment to Kelun-Biotech.<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nAssumes a share count (assuming dilution) of approximately 2.55 billion shares.<\/p>\n<\/td>\n | | <\/tr>\n<\/table>\n\nMerck continues to experience strong global underlying demand across its key pillars of growth. Consequently, Merck is raising and narrowing its full-year outlook ranges for sales and non-GAAP EPS. For GAAP EPS, Merck is lowering and narrowing its full-year outlook, attributable to a GAAP-only charge related to settlements with certain plaintiffs in the Zetia antitrust litigation.<\/p>\n \nMerck now expects full-year 2023 sales to be between $57.7 billion and $58.9 billion, including a negative impact of foreign exchange of approximately 2 percentage points, at mid-April 2023 exchange rates. This full-year outlook includes expected sales of LAGEVRIO of approximately $1.0 billion.<\/p>\n \nMerck\u2019s full-year effective income tax rate is expected to be between 17% and 18%.<\/p>\n \nMerck is lowering and narrowing its full-year 2023 GAAP EPS range to be between $5.85 and $5.97.<\/p>\n \nMerck is raising and narrowing its full-year 2023 non-GAAP EPS range to be between $6.88 and $7.00, including a negative impact of foreign exchange of approximately 4 percentage points, at mid-April 2023 exchange rates. The non-GAAP range excludes acquisition- and divestiture-related costs and costs related to restructuring programs, as well as income and losses from investments in equity securities and a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation.<\/p>\n \nA reconciliation of anticipated 2023 GAAP EPS to non-GAAP EPS and the items excluded from non-GAAP EPS are provided in the table below.<\/p>\n \n\n| \n \n$ in millions, except EPS amounts<\/p>\n<\/td>\n | \n Full Year 2023<\/b><\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nGAAP EPS<\/p>\n<\/td>\n | \n \n$5.85 to $5.97<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nDifference<\/p>\n<\/td>\n | \n \n$1.03<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nNon-GAAP EPS that excludes items listed below2<\/sup><\/p>\n<\/td>\n| \n \n$6.88 to $7.00<\/p>\n<\/td>\n | | <\/tr>\n\n| \n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nAcquisition- and divestiture-related costs<\/p>\n<\/td>\n | \n \n$2,500<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nRestructuring costs<\/p>\n<\/td>\n | \n \n400<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \n(Income) loss from investments in equity securities<\/p>\n<\/td>\n | \n \n(375)<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nCharge for Zetia antitrust litigation settlements<\/p>\n<\/td>\n | \n \n573<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nNet decrease (increase) in income before taxes<\/p>\n<\/td>\n | \n \n$3,098<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nEstimated income tax (benefit) expense<\/p>\n<\/td>\n | \n \n(470)<\/p>\n<\/td>\n | | <\/tr>\n \n| \n \nDecrease (increase) in net income<\/p>\n<\/td>\n | \n \n$2,628<\/p>\n<\/td>\n | | <\/tr>\n<\/table>\n\nIn April, Merck announced it has agreed to acquire Prometheus; the acquisition is expected to close in the third quarter of 2023. Merck\u2019s outlook does not reflect this transaction, which is expected to be accounted for as an asset acquisition, and would result in a one-time charge of approximately $10.3 billion recorded to both GAAP and non-GAAP R&D expenses in 2023, or approximately $4.00 per share. In addition, taking into consideration operational investment to advance the pipeline assets as well as the cost of financing, Merck also anticipates EPS will be negatively impacted by approximately $0.25 in the first 12 months following close. Once the transaction closes, Merck will incorporate the anticipated impacts of this acquisition in both its GAAP and non-GAAP financial outlook.<\/p>\n Earnings Conference Call<\/span><\/b><\/p>\n\nInvestors, journalists and the general public may access a live audio webcast of the earnings conference call on Thursday, April 27, at 9:00 a.m. ET via this weblink<\/a>. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures, and slides highlighting the results, will be available at www.merck.com<\/a>.<\/p>\n\nAll participants may join the call by dialing (888) 769-8514 (U.S. and Canada Toll-Free) or (517) 308-9208 and using the access code 8206435.<\/p>\n About Merck<\/b><\/p>\n \nAt Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world \u2013 and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com<\/a> and connect with us on Twitter<\/a>, Facebook<\/a>, Instagram<\/a>, YouTube<\/a> and LinkedIn<\/a>.<\/p>\nForward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA<\/b><\/p>\n \nThis news release of Merck & Co., Inc., Rahway, N.J., USA (the \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company\u2019s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.<\/p>\n \nRisks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company\u2019s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company\u2019s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and\/or regulatory actions.<\/p>\n \nThe company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company\u2019s Annual Report on Form 10-K for the year ended December 31, 2022, and the company\u2019s other filings with the Securities and Exchange Commission (SEC) available at the SEC\u2019s Internet site (www.sec.gov<\/a>).<\/p>\n \n\n| ________________________________<\/td>\n<\/tr>\n | \n| \n 1<\/sup><\/p>\n<\/td>\n | \n\n \nNet income attributable to Merck & Co., Inc.<\/p>\n<\/td>\n<\/tr>\n | \n| \n 2<\/sup><\/p>\n<\/td>\n | \n\n \nMerck is providing certain 2023 and 2022 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors\u2019 understanding of the company\u2019s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management\u2019s annual compensation is derived in part using a non-GAAP pre-tax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to this release.<\/p>\n<\/td>\n<\/tr>\n | \n| \n 3<\/sup><\/p>\n<\/td>\n | \n\n \nRegistered trademark of Seagen and Agensys.<\/p>\n<\/td>\n<\/tr>\n | \n| \n 4<\/sup><\/p>\n<\/td>\n | \n\n \nIncludes expenses for the amortization of intangible assets and purchase accounting adjustments to inventories recognized as a result of acquisitions, intangible asset impairment charges and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also includes integration, transaction and certain other costs related to acquisitions and divestitures.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \n\nMERCK & CO., INC.<\/b><\/td>\n<\/tr>\n\nCONSOLIDATED STATEMENT OF INCOME – GAAP<\/b><\/td>\n<\/tr>\n\n(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)<\/b><\/td>\n<\/tr>\n\n(UNAUDITED)<\/b><\/td>\n<\/tr>\n\nTable 1<\/b><\/td>\n<\/tr>\n\n | \n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n | \n | \nGAAP<\/b><\/td>\n | | \n% Change<\/b><\/td>\n | | <\/tr>\n \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n | \n | \n\n \n\u00a0<\/p>\n<\/td>\n | \n 1Q23<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n 1Q22<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n | <\/tr>\n \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n | \n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n| Sales<\/td>\n | | \n\n \n$<\/p>\n<\/td>\n | \n \n14,487<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n$<\/p>\n<\/td>\n | \n \n15,901<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n-9<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | <\/tr>\n \n | \n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n| Costs, Expenses and Other<\/td>\n | | \n | \n | \n | \n | \n | <\/tr>\n \n| Cost of sales<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n3,926<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n5,380<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n-27<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | <\/tr>\n \n| Selling, general and administrative<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n2,479<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n2,323<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n7<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | <\/tr>\n \n| Research and development<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n4,276<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n2,576<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n66<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | <\/tr>\n \n| Restructuring costs<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n67<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n53<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n26<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | <\/tr>\n \n| Other (income) expense, net<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n89<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n708<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n-87<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | <\/tr>\n \n| Income Before Taxes<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n3,650<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n4,861<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n-25<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | <\/tr>\n \n| Income Tax Provision<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n825<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n554<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n | \n | <\/tr>\n \n| Net Income<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n2,825<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n4,307<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n-34<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | <\/tr>\n \n| Less: Net Income (Loss) Attributable to Noncontrolling Interests<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n4<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n(3<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n | \n | <\/tr>\n \n| Net Income Attributable to Merck & Co., Inc.<\/td>\n | | \n\n \n$<\/p>\n<\/td>\n | \n \n2,821<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n$<\/p>\n<\/td>\n | \n \n4,310<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n-35<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | <\/tr>\n \n | \n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n| Earnings per Common Share Assuming Dilution<\/td>\n | | \n\n \n$<\/p>\n<\/td>\n | \n \n1.11<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n$<\/p>\n<\/td>\n | \n \n1.70<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n-35<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | <\/tr>\n \n | \n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n| Average Shares Outstanding Assuming Dilution<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n2,551<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n2,537<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n | \n | <\/tr>\n \n| Tax Rate<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n22.6<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n11.4<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | \n | \n | <\/tr>\n<\/table>\n\n\nMERCK & CO., INC.<\/b><\/td>\n<\/tr>\n\nFIRST QUARTER 2023 GAAP TO NON-GAAP RECONCILIATION<\/b><\/td>\n<\/tr>\n\n(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)<\/b><\/td>\n<\/tr>\n\n(UNAUDITED)<\/b><\/td>\n<\/tr>\n\nTable 2a<\/b><\/td>\n<\/tr>\n\n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n | <\/tr>\n \n | \n | \nGAAP<\/b><\/td>\n | | \nAcquisition and Divestiture-Related Costs (1)<\/sup><\/b><\/td>\n | \nRestructuring Costs (2)<\/sup><\/b><\/td>\n | \n(Income) Loss from Investments in Equity Securities<\/b><\/td>\n | | \nCertain Other Items<\/b><\/td>\n | | \nAdjustment Subtotal<\/b><\/td>\n | | \nNon-GAAP<\/b><\/td>\n<\/tr>\n\n | \n | \n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n| First Quarter<\/b><\/td>\n | | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | <\/tr>\n \n| Cost of sales<\/td>\n | | \n\n $<\/b><\/p>\n<\/td>\n | \n 3,926<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n545<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n29<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n | \n | \n | \n | \n\n \n574<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n$<\/p>\n<\/td>\n | \n \n3,352<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Selling, general and administrative<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n 2,479<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n20<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n1<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n | \n | \n | \n | \n\n \n21<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n2,458<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Research and development<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n 4,276<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n10<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n | \n | \n | \n | \n | \n | \n\n \n10<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n4,266<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Restructuring costs<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n 67<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n | \n | \n\n \n67<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n | \n | \n | \n | \n\n \n67<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n–<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Other (income) expense, net<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n 89<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n15<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n | \n | \n\n \n(429<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n573<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n (3<\/sup><\/p>\n<\/td>\n| \n )<\/sup><\/p>\n<\/td>\n| \n \n159<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n(70<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| Income Before Taxes<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n 3,650<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n(590<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n(97<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n429<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n(573<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n(831<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n4,481<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Income Tax Provision (Benefit)<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n 825<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n(105<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | \n (4<\/sup><\/p>\n<\/td>\n| \n )<\/sup><\/p>\n<\/td>\n| \n \n(18<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | \n (4<\/sup><\/p>\n<\/td>\n| \n )<\/sup><\/p>\n<\/td>\n| \n | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |